Molecular Imaging Articles & Analysis
27 news found
Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC). The magnitude and frequency of updates to oncology guidelines each year make it ...
ByTempus
INTRODUCTION Gabriel Krestin received his MD from the University of Cologne, Germany where he also specialized in radiology, in 1981 and his PhD (Habilitation) in 1989. From 1990–1997, he worked at the University Hospital in Zürich/CH, including a period as acting chairman of the Department of Radiology. In 1997 he moved to Erasmus MC in Rotterdam, Netherlands where he was the ...
ByFluidda
Check out the advantages that our specialized imaging agents can provide to your research! Come and visit at the World Molecular Imaging Congress (WMIC) 2022 in Miami to discover our innovative range of Viscover products and their exciting application possibilities. We look forward to seeing you to discuss your diagnostic imaging needs and to share the latest experiences in pre-clinical ...
Congratulations to investigators at Hannover School of Medicine and Heidelberg University Hospital for receiving the 2022 SNMMI Image of the Year Award and JNM Editors’ Choice Award for Overall Best Article in 2021, respectively. Both use FAPI as the primary indicator and further underscore its potential impact as a novel radiopharmaceutical. Each year, SNMMI chooses an image that best ...
BySOFIE
Akrotome Co-Founder, Dr. Jim Basilion, traveled to Europe to make invited presentations in November, 2018. Dr. Basilion delivered papers focused on the use of molecular probes for guided, precision surgery to the European Society of Molecular Imaging, the World Society of Molecular Imaging, and the Netherlands Science ...
Edinburgh Molecular Imaging Ltd (EM Imaging) and Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) today announced a clinical research collaboration to study the potential of combining EM Imaging’s in vivo optical imaging agents and Mauna Kea’s confocal laser endomicroscopy platform to diagnose cancer. The combination of novel molecular imaging agents and advanced visualisation ...
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the appointment of David E. Gauden, D.Phil. as its new Chief Executive Officer (CEO). Former CEO and Executive Chairman Jonathan Allis, D.Phil., assumes the role of Honorary Chairman of the Blue Earth Diagnostics Board of Directors. Dr. ...
MOBILion Systems, Inc., a pioneer in fast, efficient, high-resolution instrumentation for biomarker discovery, diagnostics and therapeutic development, is collaborating with an international research team to identify alterations in the metabolism of selective glycosphingolipids in specific brain regions that contribute to the early onset and progression of Parkinson’s disease. The ...
Profacgen, a US-based biotechnology company, recognizing the importance of computational technologies for pursuing advanced research in modern biology, released custom bioinformatics software development to offer support for both academic and industrial researchers to explore, understand and analyze complex biological data in a variety of biotechnology programs and projects. Bioinformatics ...
As a division of Creative Proteomics, Lipidomics is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnology and pharmaceutical companies. The company has recently announced the fully-developed MALDI-Imaging Lipidomics Service to research the distribution of lipids in tissues. Lipidomics MALDI imaging mass ...
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced results of a secondary, post-hoc analysis of data from the prospective LOCATE and FALCON clinical trials that evaluated the impact of Axumin® (fluciclovine F 18) PET/CT imaging on management of patients with recurrent prostate cancer. ...
ODS Medical, Inc., a Montreal based medical technology company, is pleased to announce a new financing round to support product engineering and regulatory work. ODS Medical is bringing together the power of machine learning and molecular imaging to develop optical biopsy tools based on Raman spectroscopy. These tools are bringing real time tissue characterization to operating rooms and diagnostic ...
Lausanne, Switzerland- March 25, 2020 - Debiopharm, a Swiss-based biopharmaceutical company announced today having entered into a worldwide, exclusive license & research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further the development of their radioligand program, now called Debio 0228, which targets the CAIX (Carbonic Anhydrase 9) enzyme to fight the ...
The new Cellvizio®platform includes significant improvements and will enable major innovations Mauna Kea Technologies announced today that it has obtained 510(k) clearance (K193416) from the U.S. Food and Drug Administration (FDA) and CE marking of the next-generation Cellvizio® endomicroscopy platform, built with the company’s new proprietary system architecture. This marks the ...
The Cellvizio®100 series system with all its different Confocal Miniprobes™ is now cleared for use with the fluorescein dye to image blood flow in the microvasculature and capillaries Mauna Kea Technologies today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Cellvizio® 100 series and all associated Confocal Miniprobes™ for ...
Edinburgh Molecular Imaging Ltd, a company developing theragnostic agents targeting cancer, today announces the closing of a £3.1 million financing, which will be used to advance new molecular targeted systemic radiotherapy agents, EMT-100 and EMT-101 to be ready for clinic development. Current investors and one new investor supported the round. EMT-100 and EMT-101 have been developed as ...
MEDPHOT consortium aims to develop light-based molecular imaging solution for pulmonary diseases Mauna Kea Technologies today announced it is part of a molecular imaging consortium that was awarded €5.4 million by the Perspective Program of the Netherlands Organization for Scientific Research (NWO). Molecular imaging provides insight into molecular and cellular processes in the body, and ...
Additional research appearing in the June online issue (open access) of European Radiology features the groundbreaking diagnostic breast cancer imaging technology introduced by Seno Medical Instruments™, Inc. (Seno Medical). This technology might not only help physicians better differentiate between benign and malignant breast lesions, but also discriminate between breast cancer molecular ...
Edinburgh Molecular Imaging (EM Imaging), the optical molecular imaging company, today announces the appointment of Dr Bernhard Sixt as Chief Executive Officer, effective immediately. Dr Sixt has 30 years of healthcare industry experience in the development and commercialisation of laboratory services, in vivo and in vitro diagnostics, and pharmaceuticals for industry leaders such as Amersham ...
SurgiMab and Quest Medical Imaging, a leader in the market for multispectral cameras, announced today that they have entered into a collaboration agreement for the upcoming Phase III clinical trial of Surgimab’s SGM-101 in fluorescent guided colorectal cancer surgery. Under the terms of the agreement, Quest Medical Imaging has received an undisclosed lump sum payment to provide 12 ...
BySurgiMab